The past 12 months have brought numerous exciting advances involving AI and related emerging technologies. Let us not fail to take a short last look at some of the more spectacular flops.
Some investment analysts are predicting a more permissive M&A market, deregulation as a catalyst for growth and fiscal policies that stimulate economic activity. And they see AI as a catalyst in the shift.
After Luigi Mangione, the man accused of killing UnitedHealthcare CEO Brian Thompson, was extradited to New York, federal prosecutors unsealed a new set of murder charges.
ICU Medical alerted customers to knockoff batteries being circulated by suppliers. Due to a risk of the batteries not holding a charge, the recall has been given the FDA’s most serious designation.
Take a virtual tour around the Radiological Society of North America (RSNA) meeting to see the sights and new technologies displayed across the vast exhibit hall floors.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
